BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 14,691 call options on the stock. This represents an increase of 454% compared to the average daily volume of 2,654 call options.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $70.00 price target on shares of BridgeBio Pharma in a research report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and set a $43.00 target price on shares of BridgeBio Pharma in a report on Monday, September 16th. UBS Group lowered their price target on BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating for the company in a report on Tuesday, May 28th. Bank of America reiterated a “buy” rating and issued a $42.00 price target on shares of BridgeBio Pharma in a report on Wednesday, September 11th. Finally, Evercore ISI lowered their price target on BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.92.
View Our Latest Analysis on BridgeBio Pharma
Insider Activity
Institutional Investors Weigh In On BridgeBio Pharma
Large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its stake in shares of BridgeBio Pharma by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 1,495,114 shares of the company’s stock worth $60,358,000 after purchasing an additional 75,564 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of BridgeBio Pharma by 22.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 803,956 shares of the company’s stock worth $24,859,000 after purchasing an additional 145,594 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of BridgeBio Pharma by 3.3% in the first quarter. Vanguard Group Inc. now owns 13,222,126 shares of the company’s stock worth $408,828,000 after purchasing an additional 421,832 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of BridgeBio Pharma in the fourth quarter worth $7,474,000. Finally, Comerica Bank grew its stake in shares of BridgeBio Pharma by 3,013.5% in the first quarter. Comerica Bank now owns 38,514 shares of the company’s stock worth $1,191,000 after purchasing an additional 37,277 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.
BridgeBio Pharma Price Performance
Shares of NASDAQ BBIO opened at $24.86 on Wednesday. BridgeBio Pharma has a 1-year low of $21.62 and a 1-year high of $44.32. The business’s fifty day moving average price is $26.37 and its two-hundred day moving average price is $27.10. The firm has a market capitalization of $4.65 billion, a PE ratio of -7.72 and a beta of 1.07.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.61. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $3.96 million. During the same period in the prior year, the business earned ($0.98) earnings per share. BridgeBio Pharma’s quarterly revenue was up 32.1% on a year-over-year basis. Equities research analysts expect that BridgeBio Pharma will post -2.49 earnings per share for the current fiscal year.
BridgeBio Pharma Company Profile
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
See Also
- Five stocks we like better than BridgeBio Pharma
- What is a SEC Filing?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Comparing and Trading High PE Ratio Stocks
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.